• 1
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 210831.
  • 2
    Kanazawa M, Palsson OS, Thiwan SI et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 255061.
    Direct Link:
  • 3
    Greenwood-van Meerveld B. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol Motil 2007; 19(Suppl. 2): 138.
  • 4
    Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397414.
  • 5
    Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006; 24: 5969.
  • 6
    Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008; 68: 98191.
  • 7
    Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61: 17582.
  • 8
    Liu Z, Sakakibara R, Odaka T et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20: 6806.
  • 9
    Ueno N, Inui A, Satoh Y. The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res Clin Pract 2010; 87: 2732.
  • 10
    Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 152731.
  • 11
    Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 97986.
  • 12
    Li Y, Nie Y, Xie J et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007; 52: 29429.
  • 13
    Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): 11437.
  • 14
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395402.
  • 15
    Shinozaki M, Kanazawa M, Sagami Y et al. Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol 2006; 41: 4914.
  • 16
    Patrick DL, Drossman DA, Frederick IO et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 40011.
  • 17
    Kanazawa M, Drossman DA, Shinozaki M et al. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 2007; 1: 6.
  • 18
    Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 6370.
  • 19
    Spielberger CD, Gorsuch RL, Lushene R et al. Manual for State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press, 1983.
  • 20
    Whitehead WE, Delvaux M, The Working Team of Glaxo-Wellcome Research, UK. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract.. Dig Dis Sci 1997; 42: 22341.
  • 21
    Bell AM, Pemberton JH, Hanson RB, Zinsmeister AR. Variations in muscle tone of the human rectum: recordings with an electromechanical barostat. Am J Physiol 1991; 260: G1725.
  • 22
    Kanazawa M, Endo M, Yamaguchi K et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil 2005; 17: 70513.
  • 23
    Mizuno T, Aoki M, Shimada Y et al. Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. J Psychosom Res 2006; 60: 917.
  • 24
    Fukudo S, Kanazawa M, Mizuno T et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage 2009; 47: 94651.
  • 25
    Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 37080.
  • 26
    Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 1993; 43: 107883.
  • 27
    Inui A, Yoshikawa T, Nagai R et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motility in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 31320.
  • 28
    Kanaizumi T, Nakano H, Matsui Y et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 3357.
  • 29
    Krevsky B, Malmud LS, Maurer AH et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293304.
  • 30
    Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997; 62: 54655.
  • 31
    Sloots CE, Poen AC, Kerstens R et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 75967.
  • 32
    Di Stefano M, Miceli E, Mazzocchi S et al. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2007; 102: 17206.
    Direct Link:
  • 33
    Cohen JE, Onyike CU, McElroy VL et al. Pharmacological characterization of an adenylyl cyclase-coupled 5-HT receptor in aplysia: comparison with mammalian 5-HT receptors. J Neurophysiol 2003; 89: 144055.
  • 34
    Liang LX, Zhang Q, Qian W, Hou XH. Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity. Chin J Dig Dis 2005; 6: 215.
  • 35
    Seto Y, Yoshida N, Kaneko H. Effects of mosapride citrate, a 5-HT4 receptor agonist, on gastric distension-induced visceromotor response in conscious rats. J Pharmacol Sci 2011; 116: 4753.
  • 36
    Sabate JM, Bouhassira D, Poupardin C et al. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008; 20: 13441.
  • 37
    Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693702.
  • 38
    Tsuchida Y, Hatao F, Fujisawa M et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut 2011; 60: 63847.